Search Results for "fluid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fluid. Results 171 to 180 of 208 total matches.

Colchicine and Other Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009  (Issue 1326)
aspiration of joint fluid and injection of a corticosteroid such as methylprednisolone or triamcinolone ...
Until the recent introduction of febuxostat (Uloric), no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid (Colbenemid, and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Med Lett Drugs Ther. 2009 Nov 30;51(1326):93-4 |  Show IntroductionHide Introduction

IV Meloxicam (Anjeso) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
prostaglandins, decrease renal blood flow, and cause fluid retention. They may cause hypertension and renal ...
The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam (Mobic, and others), which is only indicated for treatment of chronic pain associated with osteoarthritis or rheumatoid arthritis, has been available for 20 years. IV formulations of ketorolac, ibuprofen (Caldolor), and acetaminophen (Ofirmev) are also available for treatment of pain.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):100-2 |  Show IntroductionHide Introduction

Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
tolerability, minimize toxicity and drug interactions, eliminate food or fluid requirements, optimize ...
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, as a once-monthly complete regimen for intramuscular (IM) treatment of adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA...
Med Lett Drugs Ther. 2021 May 31;63(1625):81-3 |  Show IntroductionHide Introduction

A Three-Antigen Hepatitis B Vaccine (PreHevbrio)

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
or mucosal contact with infectious blood or other bodily fluids. Common risk factors include injection drug ...
The FDA has licensed PreHevbrio (VBI Vaccines), a recombinant, 3-antigen, 3-dose hepatitis B vaccine, for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults. It has been available in Israel since 2000.
Med Lett Drugs Ther. 2022 May 16;64(1650):73-5 |  Show IntroductionHide Introduction

Drugs for Breast Cancer

   
Treatment Guidelines from The Medical Letter • Jan 01, 2005  (Issue 29)
. A fluid retention syndrome presenting with weight gain, peripheral edema, pleural effusion or ascites can ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Treat Guidel Med Lett. 2005 Jan;3(29):1-6 |  Show IntroductionHide Introduction

Pharmaceutical Drug Overdose

   
Treatment Guidelines from The Medical Letter • Sep 01, 2006  (Issue 49)
the absorption of aspirin. Fluid replacement is often needed to treat intravascular volume depletion. Dextrose ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Treat Guidel Med Lett. 2006 Sep;4(49):61-6 |  Show IntroductionHide Introduction

Thiazolidinediones and Cardiovascular Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007  (Issue 1265)
from cardiovascular causes. N Engl J Med 2007; 356:2457. 3. RW Nesto et al. Thiazolidinedione use, fluid retention ...
The thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) are peripheral insulin sensitizing agents used to treat hyperglycemia in patients with type 2 diabetes; one or the other is often used as a second or third agent with metformin (Glucophage, and others) and/or a sulfonylurea such as glimepiride (Amaryl, and others). A recent report suggested that rosiglitazone may increase the incidence of myocardial infarction (MI) and cardiovascular mortality.
Med Lett Drugs Ther. 2007 Jul 16;49(1265):57-8 |  Show IntroductionHide Introduction

Comparison Table: Triptans for Migraine (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
be repeated after 2 hrs 20 or 40 mg PO; can be repeated after 2 hrs 2.5 mg PO with fluids; can be repeated ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9   doi:10.58347/tml.2023.1678b |  Show IntroductionHide Introduction

Chemotherapy for Esophageal, Gastric and Colorectal Cancers

   
Treatment Guidelines from The Medical Letter • Aug 01, 2006  (Issue 48)
, alopecia, mucositis, diarrhea, peripheral neuropathy, fatigue and asthenia. A fluid retention syndrome ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Treat Guidel Med Lett. 2006 Aug;4(48):55-60 |  Show IntroductionHide Introduction

Drugs for Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020  (Issue 1596)
celecoxib, inhibit renal prostaglandins, decrease renal blood flow, and increase fluid retention. They can ...
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Med Lett Drugs Ther. 2020 Apr 20;62(1596):57-62 |  Show IntroductionHide Introduction